Komori
Rohto Pharmaceutical (4527) · InitiativeAdvanced

Strengthening Management Oversight by Outside Directors

First written in FY2016. 4 of 6 entries say "Advanced", first in FY2020. Latest entry: FY2026.

6entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016 – FY2017AdvancedFY2020 – FY20262016: 120162017: 120172018: 020182019: 020192020: 120202021: 020212022: 020222023: 120232024: 120242025: 020252026: 12026
Same theme, other companies
Oversight structure involving outside directors and independent officersA theme 637 companies write about · 0 as a headwind · 645 as a tailwind

The whole theme swung hardest in 2023: 15 of 104 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 198 companies compared. The sentences above are computed from all 198.Comparing 200 of the theme's 645 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「The Company has adopted a company with an Audit & Supervisory Board structure and, as of the date of submission of the Securities Report, seeks to strengthen management oversight while incorporating external perspectives by appointing 5 outside directors and 3 outside Audit & Supervisory Board members」

    The Company maintains 5 outside directors, while the number of outside Audit & Supervisory Board members changed from 2 to 3, and describes the resulting oversight structure.
  2. FY2024AdvancedAnnual report

    「The Company has adopted a company with an Audit & Supervisory Board structure and seeks to strengthen management oversight while incorporating external perspectives by appointing 5 outside directors and 2 outside Audit & Supervisory Board members」

    The number of outside directors changed from 4 previously to 5, and the Company describes an oversight structure together with 2 outside Audit & Supervisory Board members.
  3. FY2023AdvancedAnnual report

    「The Company has adopted a company with an Audit & Supervisory Board structure and seeks to strengthen management oversight while incorporating external perspectives by appointing 4 outside directors and 2 outside Audit & Supervisory Board members」

    The number of outside directors changed from 3 in FY2020 to 4, and the Company describes an oversight structure incorporating external perspectives together with 2 outside Audit & Supervisory Board members.
  4. FY2020AdvancedAnnual report

    「The Company has adopted a company with an Audit & Supervisory Board structure and seeks to strengthen management oversight while incorporating external perspectives by appointing 3 outside directors and 2 outside Audit & Supervisory Board members」

    The number of outside directors changed from 2 to 3, and the Company describes an oversight structure incorporating external perspectives together with 2 outside Audit & Supervisory Board members.
  5. FY2017RestatedAnnual report

    「The Company has adopted a company with an Audit & Supervisory Board structure. By appointing 2 outside directors and 2 outside Audit & Supervisory Board members, it incorporates external perspectives while strengthening management oversight.」

    The Company reaffirms the strengthening of external oversight and management monitoring through the external perspectives of 2 outside directors and 2 outside Audit & Supervisory Board members.
  6. FY2016First statedAnnual report

    「The Company has adopted a company with an Audit & Supervisory Board structure. By appointing 2 outside directors and 2 outside Audit & Supervisory Board members, it incorporates external perspectives while strengthening management oversight.」

    The Company has 2 outside directors and 2 outside Audit & Supervisory Board members, and states that it will strengthen its monitoring functions through cooperation among the Audit & Supervisory Board, the Internal Audit Office and the accounting auditor.
Moved together

"Establishing a market position through high-value-added products and new brands" moved the same way as this thread, in the same document, in 4 of its 6 moves.

444443★123456
  1. ★This thread
  2. 1Establishing a market position through high-value-added products and new brands4×
  3. 2Technological Innovation and Strengthening the R&D Platform4×
  4. 3Globalization Centered on Asia and Expansion into Emerging Markets4×
  5. 4Management Focused on Profitability Metrics4×
  6. 5Strategic Shareholdings Held to Maintain and Develop Business Relationships4×
  7. 6Initiatives to make food and regenerative medicine future pillars of the business3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Rohto Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.